Efficacy and Safety Study of Moxidectin in Adults With Scabies
Study Details
Study Description
Brief Summary
Moxidectin is not approved to treat scabies in humans. The effective dose of moxidectin to treat scabies is not known. This study aims to assess the efficacy of a single administration of 8 mg, 16 mg, or 32 mg moxidectin per oral in achieving Scabies Complete Cure at Day 28. This study also aims to assess the safety of three strengths of single moxidectin doses in adults with scabies.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Moxidectin 8mg Moxidectin 8 mg (over encapsulated) will be administered as a single dose on Day 0. Each subject will receive the same number of capsules made up of moxidectin 2 mg over encapsulated tablets and placebo capsules to maintain the blind. |
Drug: Moxidectin Oral Product
The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required
|
| Experimental: Moxidectin 16mg Moxidectin 16 mg (over encapsulated) will be administered as a single dose on Day 0. Each subject will receive the same number of capsules made up of moxidectin 2 mg over encapsulated tablets and placebo capsules to maintain the blind. |
Drug: Moxidectin Oral Product
The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required
|
| Experimental: Moxidectin 32mg Moxidectin 32 mg (over encapsulated) will be administered as a single dose on Day 0. |
Drug: Moxidectin Oral Product
The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose.
|
| Placebo Comparator: Placebo 16 Placebo capsules will be administered as a single dose on Day 0. |
Drug: Placebo
16 placebo capsules will be administered as a single dose.
|
Outcome Measures
Primary Outcome Measures
- Proportion of index subjects achieving complete cure (Efficacy) [28 Days]
Proportion of index subjects achieving Complete Cure at Day 28. Complete Cure is defined as demonstration of both: Clinical cure: all signs of scabies have completely resolved, including burrows, inflammatory/noninflammatory lesions and pruritus. And Microscopic or dermatoscopic cure demonstrating the absence of scabies mites, eggs, and/or scybala, and negative dermoscopy for burrows.
- Incidence and severity of Treatment Emergent Adverse Event (Safety) [84 Days]
Incidence and severity of Treatment Emergent Adverse Event (TEAEs), Incidence of serious TEAEs and Incidence of TEAEs leading to study withdrawal and/or death.
Other Outcome Measures
- Proportion of index subjects achieving clinical cure without microscopic or dermatoscopic cure, assessed by skin examination to confirm all signs of scabies have completely resolved. [28 Days]
The proportion of index subjects demonstrating clinical cure without microscopic or dermatoscopic cure at Day 28.
- Proportion of index subjects achieving microscopic or dermatoscopic cure without clinical cure. Microscopic or dermatoscopic cure is assessed by demonstrating the absence of scabies mites, eggs, and/or scybala, and negative dermoscopy for burrows. [28 Days]
The proportion of index subjects demonstrating microscopic or dermatoscopic cure without clinical cure at Day 28.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Aged 18 years or older.
-
Provided written informed consent.
-
Diagnosis of active scabies infestation confirmed by the presence of clinical signs and symptoms (evidence of burrows or typical inflammatory/noninflammatory lesions and pruritus) and either microscopic confirmation of scabies mite(s), ova or scybala by skin scraping or dermoscopy.
-
All female subjects of childbearing potential must agree to the use of a highly effective method of birth control until 3 months after administration of Investigational Product (IP).
Exclusion Criteria:
-
Diagnosis of crusted/Norwegian scabies or scabies presentation that, in the opinion of the Investigator, would require treatment with more than one standard of care treatment for scabies (e.g., scabies requiring concurrent topical and oral treatment).
-
History of chronic or recurrent dermatologic disease or skin conditions other than scabies that could interfere with the diagnosis of scabies and evaluation of cure.
-
Received any treatment with one or more scabicides within the 28 days prior to Screening, or between Screening and Baseline, including but not limited to permethrin, ivermectin, benzyl benzoate, sulfur, lindane, crotamiton, malathion, tea tree oil or spinosad.
-
Body mass index > 35 kg/m2.
-
Creatinine clearance < 30 mL/min (using Cockcroft-Gault equation).
-
Both total bilirubin >1.5 x upper limit of normal (ULN) and aspartate aminotransferase (AST) > ULN.
-
Abnormal and clinically relevant findings in hematology or biochemistry assessments at Screening, or in vital signs, 12-lead electrocardiogram (ECG), or physical examination at Screening and/or Baseline, that in the opinion of the Investigator would put the subjects at increased risk from participating in the study, confound study evaluations, or may interfere with study conduct.
-
Presence of any other clinically relevant condition, including infection, immunological disorder, malignant disease, and/or other underlying condition or circumstance at Screening or Baseline that in the opinion of the Investigator would put the subjects at increased risk from participating in the study, confound study evaluations, or interfere with the study conduct.
-
Use of topical steroids, systemic or high-dose inhaled corticosteroids (>500 μg per Day of fluticasone propionate or equivalent for adults), or other immunomodulators within 14 days of Baseline.
-
Requiring ongoing treatment with, or received within 5 half-lives before Screening, any of the following medications that are clinical breast cancer resistance protein (BCRP) inhibitors: curcurmin (turmeric) supplements, cyclosporine A, darolutamide, eltrombopag, febuxostat, fostamatinib, rolapitant and teriflunomide.
-
Received an investigational agent within 28 days of Screening (or 5 half-lives of the investigational agent, whichever is longer).
-
Known or suspected hypersensitivity to macrocyclic lactones or excipients used in the formulation of moxidectin.
-
Known, suspected or at risk of Loa loa coinfection.
-
Difficulty swallowing tablets or capsules.
-
Pregnant or breastfeeding or planning to become pregnant from Screening until 3 months after treatment with IP.
-
Known or suspected alcohol or illicit substance abuse.
-
Unwilling, unlikely or unable to comply with all protocol specified assessments.
-
Previous enrolment in this study.
-
Previous moxidectin exposure within 6 months (5-half-lives) from Baseline.
-
Has household members who refuse or are unable to receive permethrin 5% cream treatment for scabies.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Medicines Development for Global Health
Investigators
- Principal Investigator: Oscar De Valle, MD, West Houston Clinical Research Service
- Principal Investigator: Jennifer L Parish, MD, Paddington Testing Company, Inc
- Principal Investigator: Richard L Fernandez, MD, Advance Care and Clinical Trials
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- MDGH-MOX-2002